FLT3 mutations in myeloproliferative neoplasms: The beaumont experience

Diagnostic Molecular Pathology

Volumn 22, Issue 3, 2013, Pages 156-160

  Williams, Lindsay ^a   Kelley, Harlan H ^b   Meng, Xiuling ^c   Prada, Anne ^a   Crisan, Domnita ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b Northern Navajo Medical Center   (United States)

^c UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

FLT3; JAK2; myelodysplastic myeloproliferative neoplasm; myeloproliferative neoplasm

Indexed keywords

RESTRICTION ENDONUCLEASE;

ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; DNA EXTRACTION; FLT3 GENE; GEL ELECTROPHORESIS; GENE DUPLICATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GRANULOCYTIC SARCOMA; HUMAN; HUMAN TISSUE; JANUS KINASE 2 GENE; MALE; MYELOPROLIFERATIVE NEOPLASM; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; TUMOR GENE;

EID: 84883457828     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31828564fe     Document Type: Article

References (31)

1. Small D. FLT3 Mutations: biology and treatment. Hematology Am Soc Hematol Educ Program. 2006;2006:178-184.
2. Lyman S, Jacobsen S. C-Kit ligand and FLT3 ligand: stem/ progenitor cell factors with overlapping yet distinct activities. Blood. 1998;91:1101-1134. (Pubitemid 28086863)
3. Gilliland D, Griffin J. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532-1542. (Pubitemid 34925124)
4. Levis M, Small D. FLT3: It does matter in leukemia. Leukemia. 2003;17:1738-1752.
5. Stirewalt D, Radich J. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3:650-665. (Pubitemid 37328820)
6. Litzow M. More flitting about FLT3. Blood. 2005;106:3331-3332. (Pubitemid 41609152)
7. Levis M, Pham R, Smith B, et al. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood. 2004;104:1145-1150. (Pubitemid 39038036)
8. Ozeki K, Kiyoi H, Hirose Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood. 2004;103:1901-1908. (Pubitemid 38268989)
9. Li Y, Li H, Wang MN, et al. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti- FLT3 neutralizing antibody. Blood. 2004;104:1137-1144. (Pubitemid 39038035)
10. Reindl C, Bagrintseva K, Vempati S, et al. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood. 2006;107:3700-3707.
11. Georgiou G, Karali V, Zouvelou C, et al. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. Br J Haematol. 2006; 134:302-306. (Pubitemid 43990791)
12. Shih LY, Lin TL, Wang PN, et al. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. Cancer. 2004;101: 989-998.
13. Bains A, Luthra R, Medeiros LJ, et al. FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol. 2011;135:62-69.
14. Pinheiro RF, de Sa Moreira E, Silva MR, et al. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia. Cancer Genet Cytogenet. 2008;183:89-93. (Pubitemid 351707708)
15. Bacher U, Haferlach T, Kern W, et al. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica. 2007;92:744-752. (Pubitemid 350155299)
16. Daver N, Strati P, Jabbour E, et al. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013;88:56-59.
17. Li L, Piloto O, Nguyen HB, et al. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood. 2008;111:3849-3858.
18. Greenblatt S, Li L, Slape C, et al. Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model. Blood. 2012;119:2883-2894.
19. Lin P, Jones D, Medeiros LJ, et al. Activating FLT3 mutations are detectable in chronic and blast phases of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol. 2006;126:530-533. (Pubitemid 44498502)
20. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia. 1997;11:1605-1609. (Pubitemid 27458595)
21. Pardanani A, Reeder TL, Kimlinger TK, et al. FLT3 and C-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res. 2003;27: 739-742. (Pubitemid 36683263)
22. Abu-Duhier FM, Goodeve AC, Care RS, et al. Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis. Br J Haematol. 2003;120:464-470. (Pubitemid 36241503)
23. Swerdlow S, Campo E, Harris NL, et al. The International Agency for Research on Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2008:31-85.
24. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom medical research council AML 10 and 12 trials. Blood. 2001;98:1752-1759.
25. Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89-94. (Pubitemid 32061246)
26. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434-2439. (Pubitemid 32291491)
27. Horiike S, Yokota S, Nakao M, et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia. 1997;11:1442-1446. (Pubitemid 27404382)
28. Xu F, Taki T, Yang HW, et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br J Haematol. 1999;105:155-162. (Pubitemid 29197158)
29. Suzuki M, Abe A, Kiyoi H, et al. Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation. Leukemia. 2006;20:1168-1169. (Pubitemid 43797316)
30. Medeiros BC, Zhang T, Lipton JH, et al. Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia. Am J Hematol. 2007;82:293-294. (Pubitemid 46564325)
31. Kim KI, Park J, Ahn KS, et al. Molecular characterization and prognostic significance of FLT3 in CML progression. Leuk Res. 2010;34:995-1001.